Home Compare JAZZ vs WRB
Stock Comparison · Structural lead, mixed market

Jazz Pharmaceuticals vs W. R. Berkley: Which Stock Looks Stronger in 2026?

Structurally, Jazz Pharmaceuticals and W. R. Berkley are closely matched — neither holds a meaningful edge overall. W. R. Berkley still leads on profitability and stability, which keeps the comparison from looking entirely one-sided. On the market side, Jazz Pharmaceuticals is in better shape — its trend is intact while W. R. Berkley's trend has broken down.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

On growth, the clearer edge sits with Jazz Pharmaceuticals plc, while the broader score remains level.

Trajectory Similarity
0.66
Moderately similar
Peer-set rank: #10
within Jazz Pharmaceuticals plc's functional peer set

These two companies are linked by measured long-term financial trajectory similarity within the selected peer universe.

A moderate similarity means the pair is structurally comparable, but not a near-twin trajectory match.

The match is driven mainly by investment intensity and revenue stability.

Similarity drivers
investment intensityrevenue stability
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
JAZZ
Jazz Pharmaceuticals plc
56
Peer-Score
Signal qualityHigh
vs
WRB
W. R. Berkley Corporation
56
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: JAZZ vs WRB Profitability 35 68 Stability 44 70 Valuation 88 68 Growth 48 5 JAZZ WRB
Gap Ranking
#1 Growth +43
#2 Profitability +33
#3 Stability +26
#4 Valuation +20
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for JAZZ and WRB Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer JAZZWRB Relative valuation Structural strength

The setup is mixed: neither company clearly combines the stronger profile with the more supportive price setup.

Valuation position uses Forward P/E and peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Growth
Growth also leans toward Jazz Pharmaceuticals plc, reinforcing the broader structural lead.
Profitability
W. R. Berkley Corporation ranks near the top of the group on profitability; Jazz Pharmaceuticals plc sits in the weaker half.
Growth — Dominant Gap
JAZZ
48
WRB
5
Gap+43in favour of JAZZ

Earnings growth is one contributing factor within the growth lead.

What keeps the gap from being one-sided

Capital efficiency also runs the other way, with a 24.4-point ROIC edge acting as a real counterforce.

What this means for the comparison

Growth is the clearest driver of the lead, with profitability adding further support — though profitability still provides a real counterweight.

Explore full peer positioning in AssetNext

Break down the JAZZ vs WRB comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other comparisons with conflicting dimension signals

Explore how JAZZ and WRB each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.